logo
Site Network

Menu

Source Legend
  • Human-provided

    Entered or confirmed by an authorized person.

  • Google

    Imported Google information.

  • Trial-derived

    Calculated or extracted directly from associated trial records.

  • AI-inferred

    A capability inferred from trial history.

  • AI-extracted

    An explicit statement extracted from an official source.

  • Public registry

    Information from a public registry.

  • Site record

    Information held in the site record.

Source: Site record. Ospedale Regina Elena

+390652661
protocollo@cert.ifo.it
Source: Site record.
http://www.ifo.it

Claim This Site

Are you the site administrator? Claim this site to update information.

Basic Information

Site Overview

Source: Human-provided.

Ospedale Regina Elena is a prominent public healthcare facility and center of excellence for oncological research and care. Formally known as the Istituto Nazionale Tumori Regina Elena (IRE), it operates under the umbrella of the Istituti Fisioterapici Ospitalieri (IFO) alongside the San Gallicano Dermatological Institute. Founded in 1933 and recognized since 1939 as an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), the hospital tightly integrates advanced biomolecular diagnostics, high-volume precision oncology surgeries (including extensive robotic procedures), and experimental translational therapies.

Business Status

Source: Human-provided. OPEN

Business Category

Source: Human-provided. Hospital

Business Subcategory

Source: Human-provided. Hospital
Source: Trial-derived.
29Total Trials
Source: Trial-derived.
6Recruiting Trials
Source: Trial-derived.
7Active Trials
Source: Trial-derived.
0Completed Trials
Source: Trial-derived.
43Unique Conditions
Source: Trial-derived.
54Unique Sponsors

Conditions

Source: Trial-derived. Non Small Cell Lung Cancer (3)Source: Trial-derived. Non-small Cell Lung Cancer (2)Source: Trial-derived. Ovarian Cancer (2)Source: Trial-derived. Advanced BRAFV600 Wild-type Melanoma (1)Source: Trial-derived. Advanced Ovarian Cancer (1)Source: Trial-derived. Adverse Drug Event (1)Source: Trial-derived. BCR-ABL Positive (1)Source: Trial-derived. Blood Pressure (1)

Sponsors

Source: Trial-derived. Hoffmann-La Roche (4)Source: Trial-derived. Merck Sharp & Dohme LLC (3)Source: Trial-derived. AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology (2)Source: Trial-derived. AstraZeneca (2)Source: Trial-derived. Daiichi Sankyo (2)Source: Trial-derived. EMD Serono Research & Development Institute, Inc. (2)Source: Trial-derived. Gruppo Italiano Malattie EMatologiche dell'Adulto (2)Source: Trial-derived. Gruppo Oncologico Italiano di Ricerca Clinica (2)

Research Technology

Research technology inferred from trial participation

Source: AI-inferred. Electronic data capture

Imaging & Diagnostics

Imaging and diagnostic capabilities inferred from trial participation

Source: AI-inferred. 12-lead ECG

Laboratory & Biospecimens

Laboratory and biospecimen capabilities inferred from trial participation

Source: AI-inferred. Clinical laboratory testing
Source: AI-inferred. Specimen packaging and shipment
Source: AI-inferred. Sequencing / genomics
Source: AI-inferred. Timed pharmacokinetic sampling and processing

Research Pharmacy & Investigational Product

Investigational-product capabilities inferred from trial participation

Source: AI-inferred. Hazardous / cytotoxic drug handling

Clinical Procedures

Clinical procedures inferred from trial participation

Source: AI-inferred. Intravenous infusion administration

Accessibility & Parking

Accessibility Features

Source: Google. Wheelchair accessible entrance
Source: Google. Wheelchair accessible parking lot

Additional Capabilities

Other capabilities inferred from trial participation

Source: AI-inferred. Serial radiological tumour imaging